DCM
DAFNA Capital Management’s Mersana Therapeutics MRSN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-734,038
| Closed | -$932K | – | 78 |
|
|
2023
Q3 | $932K | Sell |
734,038
-76,807
| -9% | -$97.5K | 0.29% | 58 |
|
|
2023
Q2 | $2.67M | Buy |
810,845
+299,982
| +59% | +$987K | 0.73% | 38 |
|
|
2023
Q1 | $2.1M | Buy |
510,863
+97,400
| +24% | +$400K | 0.63% | 38 |
|
|
2022
Q4 | $2.42M | Buy |
413,463
+35,700
| +9% | +$209K | 0.68% | 41 |
|
|
2022
Q3 | $2.55M | Sell |
377,763
-29,000
| -7% | -$196K | 0.69% | 38 |
|
|
2022
Q2 | $1.88M | Buy |
406,763
+54,000
| +15% | +$249K | 0.51% | 47 |
|
|
2022
Q1 | $1.41M | Buy |
352,763
+212,500
| +152% | +$848K | 0.37% | 61 |
|
|
2021
Q4 | $872K | Hold |
140,263
| – | – | 0.22% | 66 |
|
|
2021
Q3 | $1.32M | Buy |
140,263
+12,000
| +9% | +$113K | 0.35% | 62 |
|
|
2021
Q2 | $1.74M | Buy |
128,263
+4,000
| +3% | +$54.3K | 0.36% | 55 |
|
|
2021
Q1 | $2.01M | Buy |
124,263
+75,000
| +152% | +$1.21M | 0.48% | 50 |
|
|
2020
Q4 | $1.31M | Sell |
49,263
-103,500
| -68% | -$2.75M | 0.39% | 53 |
|
|
2020
Q3 | $2.84M | Sell |
152,763
-117,400
| -43% | -$2.19M | 0.92% | 27 |
|
|
2020
Q2 | $6.32M | Sell |
270,163
-131,456
| -33% | -$3.08M | 1.82% | 18 |
|
|
2020
Q1 | $2.34M | Buy |
401,619
+293,156
| +270% | +$1.71M | 0.98% | 29 |
|
|
2019
Q4 | $621K | Sell |
108,463
-393,273
| -78% | -$2.25M | 0.21% | 67 |
|
|
2019
Q3 | $793K | Buy |
501,736
+226,500
| +82% | +$358K | 0.3% | 63 |
|
|
2019
Q2 | $1.12M | Sell |
275,236
-128,064
| -32% | -$519K | 0.42% | 56 |
|
|
2019
Q1 | $2.12M | Buy |
+403,300
| New | +$2.12M | 0.92% | 32 |
|